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Background: Thyrotoxicosis and hypothyroidism are associated with fatigue. Here we studied euthyroid sub-
jects to determine if there was a relationship between serum thyrotropin (TSH), free thyroxine (FT4) and thyro-
peroxidase antibodies and fatigue.
Methods: A total of 5897 participants of the Nijmegen Biomedical Study received a questionnaire and serum
TSH (normal range 0.4–4.0 mIU/L) and FT4 (normal range 8–22 pmol/L) were measured. Fatigue was evaluated
by the RAND-36 and the shortened fatigue questionnaire (SFQ).
Results: Euthyroid subjects with a serum TSH level of 0.4–1.0 mIU/L had a lower RAND-36 vitality score (65.2
vs. 66.8; regression coefficient (RC) - 1.6 [95% confidence interval (CI) - 2.6 to - 0.5]; p= 0.005) and a higher SFQ
score (11.7 vs. 11.0; RC 0.6 [CI 0.2–1.0]; p= 0.004) than those with a TSH of 1.0–2.0 mIU/L. Those with a serum FT4
of 18.5–22 pmol/L reported fatigue more often (52.5% vs. 33.3%; relative risk (RR) 1.4 [CI 1.0–1.9]; p= 0.03), had a
lower RAND-36 vitality score (61.7 vs. 66.6; RC - 4.4 [CI - 8.1 to - 0.6]; p= 0.02) and a higher SFQ score (13.2 vs.
11.0; RC 1.9 [CI 0.4–3.3]; p= 0.01) than subjects with a FT4 level of 11.5–15 pmol/L. In comparison to euthyroid
subjects without known thyroid disease, euthyroid subjects with previously known thyroid disease reported
fatigue more often (52.3% vs. 34.0%; RR 1.3 [CI 1.0–1.5]; p= 0.025), had a lower RAND-36 vitality score (61.4 vs.
66.3; RC - 2.9 [CI - 5.3 to - 0.6]; p= 0.015) and a higher SFQ score (13.7 vs. 11.1; RC 1.4 [CI 0.5–2.3]; p= 0.002).
Conclusion: In euthyroid individuals without a history of thyroid disease, there is a modest relationship between
thyroid function and fatigue with subjects having an apparently higher production of T4 experiencing more
fatigue. Subjects with a history of thyroid disease, but with normal TSH and FT4 concentrations, experience more
fatigue than the general population. The reasons for this are unclear, but subtle abnormalities in the dynamics of
thyroid hormone secretion should be considered.
Introduction
Thyroid dysfunction is common in the general popula-tion (1–4). Fatigue is a frequently reported symptom of
patients with both hyper- and hypothyroidism (5–9). Fatigue
is also one of the most relevant symptoms for patients with
thyroid dysfunction impairing their quality of life (9,10). As
for mild degrees of thyroid dysfunction, Canaris et al. re-
ported more symptoms, including feeling more tired, in
subclinically hypothyroid subjects in comparison to euthy-
roid subjects in a large population-based study (2). In con-
trast, Grabe et al. found no increase of fatigue in subjects
with subclinical and overt hypo- or hyperthyroidism in a
population-based study (11).
In the absence of suitable methods for measuring thyroid
hormone and thyrotropin (TSH) production rates in groups of
patients, by generally accepted definition, subjects with
serum TSH and free thyroxine (FT4) concentrations within the
normal range are considered to be euthyroid. Previous studies
have shown an association between variations in serum TSH
and FT4 concentrations within the normal range and cardio-
vascular risk, blood pressure, body mass index (BMI), inci-
dence of atrial fibrillation, and serum cholesterol (12–17).
These results raise the question of whether there is also an
association between fatigue and serum TSH and FT4 within
the normal range. Recently, an association between the level
of thyroperoxidase antibodies (TPOAbs) and fatigue has been
described in euthyroid women with a goiter (18).This raises
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the question whether TPOAb levels are associated with fa-
tigue in the general population.
The present study had several goals. The first was to in-
vestigate whether unsuspected thyroid dysfunction (i.e.,
overt or subclinical thyrotoxicosis or overt or subclinical hy-
pothyroidism) as uncovered in a population, was associated
with the prevalence and severity of fatigue. The second was to
investigate whether, in subjects whose serum TSH and FT4 are
in the normal range, there is a relationship between the levels
of serum TSH or serum FT4 and the prevalence and severity of
fatigue. The last was to determine in apparently euthyroid
subjects (i.e., normal TSH and FT4) whether there is an asso-
ciation between the presence of TPOAbs and fatigue.
Methods
Study participants
The subjects of this study were participants of the Nijmegen
Biomedical Study, a large, population-based survey per-
formed in Nijmegen, a town in the eastern part of The
Netherlands. Details of this study have been described pre-
viously (4). Approval to conduct the study was obtained from
the Institutional Review Board. A total of 22,451 age- and sex-
stratified randomly selected adults received a questionnaire
on lifestyle, medical history, and symptoms. Of each age-
group (range 5 years), 750 men and 750 women were invited
to participate. We excluded pregnant women and subjects
using medication interfering with thyroid function, such as
lithium, amiodarone, kelp, oral glucocorticosteroids, and/or
dopamine agonists because of the possible effect of these
conditions and medications on thyroid function. To investi-
gate the population without known thyroid disease, we ex-
cluded the subjects with previously known thyroid disease,
subjects using thyromimetic and/or thyrostatic drugs, and
subjects with a history of thyroid surgery and/or 131I
treatment.
Laboratory methods
Serum TSH was measured by an immunoluminometric
assay on a random access analyzer (Architect; Abbott Diag-
nostics Division). The reference interval used in our labora-
tory is 0.4–4.0 mIU/L. Serum FT4 was measured with a
luminescence enzyme immunoassay on a random-access
assay system (Vitros ECI; Ortho Clinical Diagnostics). Our
laboratory reference interval is 8.0–22.0 pmol/L. Antibodies
against TPO (TPOAbs) were measured with a fluorescence
immunoenzymometric assay for the quantitative measure-
ment of the immunoglobulin G class of anti-TPOAbs (AxSYM
Anti-TPO; Abbott Diagnostics Division). The reference inter-
val was defined as < 12 kIU/L (data provided by manufac-
turer). More details about these measurements are described
elsewhere (4). Thyroid function was classified as overt thyro-
toxicosis if TSH was < 0.4 mIU/L and FT4 was > 22 pmol/L
and it was classified as subclinical thyrotoxicosis if TSH was
< 0.4 mIU/L and FT4 was ‡ 8 and £ 22 pmol/L. Thyroid
function was classified as overt hypothyroidism if TSH was
> 4.0 mIU/L and FT4 was < 8 pmol/L and as subclinical hy-
pothyroidism if TSH was > 4.0 mIU/L and FT4 was ‡ 8 and
£ 22 pmol/L. When both TSH and FT4 were within normal
range, thyroid function was classified as euthyroidism. When
either TSH or FT4 was not within the normal range, thyroid
function was classified as thyroid dysfunction. Subjects with
overt thyrotoxicosis, subclinical thyrotoxicosis, overt hypo-
thyroidism, or subclinical hypothyroidism were considered to
have thyroid dysfunction.
Questionnaire
The questionnaire contained questions about gender, age,
weight, height, lifestyle, medical history, and the use of
medication. The presence of the symptom fatigue was eval-
uated by the question: ‘‘Do you feel tired?’’ Data on the
presence of the symptom fatigue were missing in 119 subjects.
The subscale vitality (energy and fatigue) of the RAND-36
Item Health Survey 1.0 was used to determine the intensity of
fatigue (19).The items of the subscale vitality are identical to
the MOS SF-36 (20). The subscale vitality of the RAND-36,
translated in Dutch, has a good internal reliability (Cronbachs
a: 0.82) (21,22). It consists of four questions: ‘‘How much of the
time during the past 4 weeks—did you feel full of life?—did
you have a lot of energy?—did you feel worn out?—did you
feel tired?’’ The participants choose the best option of the six
possible answers given for each question: ‘‘all of the time,’’
‘‘most of the time,’’ ‘‘a good bit of the time,’’ ‘‘some of the
time,’’ ‘‘a little of the time,’’ or ‘‘none of the time.’’ All items
were scored on a 0–100 range and recoded so that a high score
defined a more favorable health state. The average score of the
four questions was calculated. When one or two items were
missing, the average score of the other two or three questions
was used. If three or four items were missing, the total score
was defined as missing and not used for the analyses. The
score of the subscale vitality of the RAND-36 was missing in
178 subjects. A higher score is associated with having more
energy and less fatigue, with a maximum score of 100. The
average score of the subscale vitality of the RAND-36 in a
Dutch cohort consisting of 1063 subjects, aged 18–89 years,
was 67.4 – 19.9 (22). In this cohort, young adults (19–24 years
old) scored on average 69.2 points, whereas elderly (75–85
years old) scored on average 60.1 points.
In addition, the shortened fatigue questionnaire (SFQ) was
also used to determine the intensity of the fatigue (23,24). The
SFQ is a short and easy to use instrument to determine the
intensity of fatigue. The SFQ has a good internal reliability
(Cronbach a: 0.88) and discriminating validity. It consists of
four statements: ‘‘I feel tired,’’ ‘‘I tire easily,’’ ‘‘I feel fit,’’ and ‘‘I
feel physically exhausted.’’ The participants rated the state-
ments for the degree of being true at a 7-point scale and for
each answer, points were granted. A higher score is associated
with being more tired, with a maximum score of 28 points.
Healthy adults, without any stressful conditions, score on
average 5–8 points, whereas, for example, patients with can-
cer score on average 13–21 points (23).The SFQ score was
missing in 497 subjects.
Statistical analysis
The BMI was calculated by dividing the body weight (kg)
by the square of the height (m). Relative risks (RRs) along
with the 95% confidence intervals (CIs) were estimated
using loglinear regression analyses, with fatigue as the
dependent variable and thyroid function class and TSH and
FT4 subclasses within the normal range as the independent
variables (25–27). Also the presence of TPOAbs (defined as
> 12 kIU/mL according to the reference interval provided
THYROID FUNCTION AND FATIGUE 1237
by the manufacturer) and the presence of known thyroid
disease were used as independent variables in the loglinear
analysis.
To compare the score of the vitality subscale of the RAND-
36 and the SFQ score of each thyroid function class, we used
linear regression analyses with the fatigue score as the de-
pendent variable and thyroid function class as the indepen-
dent variable. Within the normal range of thyroid function,
we used subclasses of TSH and FT4 for linear regression an-
alyses with the score of the subscale vitality of the RAND-36
or the SFQ score as the dependent variable and the TSH
subclasses and FT4 subclasses as the independent variables.
TPOAb levels were also used as the independent variables for
linear regression analyses with the score of the subscale vi-
tality of the RAND-36 or the SFQ score as the dependent
variable.
All regression analyses were adjusted for gender, age, BMI,
and smoking status to eliminate possible confounders. In
addition, we adjusted for a medical history of chronic ob-
structive pulmonary disease (COPD)/asthma, rheumatoid
disease, cardiovascular disease (CVD), cancer, diabetes mel-
litus, kidney disease, liver disease, and C-reactive protein
(CRP) to rule out the possible confounding effect of non-
thyroidal illness. We analyzed the data with STATA version
11.0 (StataCorp, Texas).
Results
A total of 9350 subjects receiving a questionnaire re-
sponded (response rate: 42%). Of the responders, 6434 sub-
jects (69%) gave permission for blood withdrawal. The
subjects who gave permission for blood withdrawal differed
only slightly from the subjects who did not donate blood
samples: the mean age was 56 vs. 53 years, the percentage of
women was 54% vs. 50%, the prevalence of fatigue was 36%
vs. 37%, the mean RAND-36 vitality score was 65.7 vs. 63.9,
and the SFQ score was 11.4 vs. 12.2, respectively. We excluded
47 pregnant women and 162 subjects using medications in-
terfering with thyroid function. In addition, we excluded 328
subjects because of previously-known thyroid disease.
The characteristics of the remaining 5897 subjects are
shown in Table 1. Their age ranged from 18 to 98 years. Fe-
male gender, a higher age, a higher BMI, and a medical history
of CVD, cancer, diabetes, rheumatoid arthritis, asthma/
COPD, renal disease, liver disease, and a high CRP were all
associated with a higher prevalence of fatigue.
Table 2 shows the prevalence of self-reported fatigue, the
RAND-36 vitality subscale score, and the SFQ score according
to the thyroid function class. Subjects with thyroid dysfunc-
tion reported fatigue more frequently (39.6%) than euthyroid
subjects (34.0%), but this difference was not statistically sig-
nificant. The RR was 1.2 [CI 0.996–1.4], p = 0.055. After ad-
justment for possible confounders, the RR was 1.1 [CI 0.9–1.3],
p = 0.34. There was no statistically significant difference in the
RAND-36 score or the SFQ score between euthyroid subjects
and subjects with thyroid dysfunction, neither before nor after
adjustment for possible confounders.
The prevalence of fatigue, the score of the subscale vitality
of the RAND-36 and the SFQ score by TSH and FT4 subclasses
within the normal range (i.e., in euthyroid subjects) are shown
in Table 3.Within the normal range of TSH, subjects with a
TSH level of 0.4–1.0 mIU/L had a lower RAND-36 vitality
score (65.2 vs. 66.8; mean difference - 1.6 [CI - 2.6 to - 0.5];
p = 0.005) and a higher SFQ score (11.7 vs. 11.0; mean differ-
ence 0.6 [CI 0.2–1.0]; p= 0.004) than those with a serum TSH of
1.0–2.0 mIU/L, after adjustment for possible confounders.
Subjects with a serum FT4 level of 18.5–22 pmol/L reported
fatigue more often (52.5% vs. 33.3%; RR 1.4 [CI 1.0–1.9];
p = 0.03), had a lower RAND-36 vitality score (61.7 vs. 66.6;
mean difference - 4.4 [CI - 8.1 to - 0.6]; p = 0.02) and a higher
Table 1. Characteristics of the Population
Total Female Male
Characteristic n = 5897 n = 3101 n = 2796
Age (years) 55.6 – 17.9 53.1 – 18.1 58.5 – 17.2
BMI (kg/m2) 25.2 – 4.1 24.8 – 4.5 25.6 – 3.6
Smoking [n (%)] 1327 (22.5%) 652 (21.0%) 675 (24.1%)
Medical history of
COPD/asthma [n (%)] 725 (12.3%) 375 (12.1%) 350 (12.5%)
CVD [n (%)] 586 (9.9%) 161 (5.2%) 425 (15.2%)
Rheumatic disease [n (%)] 502 (8.5%) 329 (10.6%) 173 (6.2%)
Cancer [n (%)] 453 (7.7%) 229 (7.4%) 224 (8.0%)
Diabetes mellitus [n (%)] 321 (5.4%) 145 (4.7%) 176 (6.3%)
Kidney disease [n (%)] 173 (2.9%) 87 (2.8%) 86 (3.1%)
Liver disease [n (%)] 138 (2.3%) 79 (2.5%) 59 (2.1%)
CRP > 10 mg/L [n (%)] 544 (9.2%) 290 (9.4%) 254 (9.1%)
Fatigue [n (%)] 1989 (34.4%) 1195 (39.5%) 794 (28.9%)
RAND-36 score 66.2 – 17.4 64.1 – 17.3 68.6 – 17.3
SFQ score 11.2 – 6.4 12.0 – 6.6 10.3 – 6.1
TSH (mIU/L) 1.4 (0.9–2.0) 1.4 (0.9–2.0) 1.4 (0.9–1.9)
FT4 (pmol/L) 13.3 (12–14.6) 13.3 (12–14.6) 13.3 (12–14.7)
TPOAbs positive [n (%)] 747 (12.7%) 520 (16.8%) 227 (8.1%)
Euthyroid [n (%)] 5439 (92.2%) 2823 (91.0%) 2616 (93.6%)
Data are reported as number (percent), mean– standard deviation, or median (IQR).
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; CRP, C-reactive protein; FT4, free
thyroxine; IQR, interquartile range; SFQ, shortened fatigue questionnaire; TSH, thyrotropin; TPOAbs, thyroperoxidase antibodies.
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SFQ score (13.2 vs. 11.0; mean difference 1.9 [CI 0.4–3.3];
p=0.01) than subjects with a serum FT4 level of 11.5–15 pmol/L.
Of the 1493 subjects with a TSH level between 0.4 and
1.0 mIU/L, 2.7% of the subjects (40 subjects) had a FT4 level
between 18.5 and 22 pmol/L. These 40 subjects reported fatigue
more often (58% vs. 36%; RR 1.6 [CI 1.2–2.2]; p=0.001), had a
(not statistically significant) lower RAND-36 vitality subscale
score (62.2 vs. 65.2; regression coefficient (RC) -3.2 [CI - 9.0–
2.5]; p = 0.27) and a higher SFQ score (13.6 vs 11.6; RC 2.2 [CI
0.1–4.3]; p = 0.04) than subjects with a TSH level between 0.4
and 1.0 mIU/L and a FT4 level between 8 and 18.5 pmol/L.
Of the 91 subjects with a FT4 level between 18.5 and 22 pmol/
L, 44.0% of the subjects (40 subjects) had a TSH level between
0.4 and 1.0 mIU/L. These 40 subjects did not differ from the
51 subjects with a TSH level between 1.0 and 4.0 mIU/L in
self-reported fatigue, the RAND-36 vitality subscale score,
and the SFQ score (self-reported fatigue 58% vs. 48%; RR 1.4
[CI 0.9–2.1]; p = 0.11; RAND-36 vitality subscale score 62.2 vs.
61.3; RC - 0.2 [CI - 7.6–7.3]; p = 0.97; SFQ score 13.6 vs. 12.8;
RC 1.5 [CI - 1.3–4.3]; p = 0.30). There were no differences in
gender, BMI, smoking status, or comorbidity between the
subclasses of TSH and FT4. However, subjects with a TSH
level of 0.4–1.0 mIU/L and subjects with a serum FT4 level of
18.5–22 pmol/L were older (mean age 57.9 and 67.2 years,
respectively) than the reference group (mean age 54.6 and
54.1 years, respectively). Subanalyses using different age
groups gave similar results regarding the association be-
tween the subclasses of TSH and FT4 levels within the nor-
mal range and fatigue (self-reported fatigue, RAND-36
vitality subscale score, and SFQ score) (data not shown).
There was no association between the prevalence of self-
reported fatigue, the RAND-36 vitality subscale score or the
SFQ score and the presence of TPOAbs, neither in euthyroid
subjects nor in subjects with thyroid dysfunction (Table 4).
Subdividing the subjects with TPOAbs according to the level
of TPOAbs did not change these results (data not shown).
When comparing the study population with the subjects
excluded because of previously known thyroid disorder, sub-
jects with a known thyroid disorder reported fatigue more
often (50% vs. 34.4%, RR 1.2 [CI 1.0–1.4]; p= 0.03), had a lower
RAND-36 vitality score (61.8 vs. 66.2; mean difference - 2.6 [CI
- 4.5 to - 0.6]; p= 0.01) and a higher SFQ score (13.5 vs. 11.2;
mean difference 1.3 [CI 0.6–2.1]; p< 0.001) than subjects without
known thyroid disorder (Table 5). Even in subjects who had
serum TSH and FT4 concentrations in the normal range, those
with previously known thyroid disease reported fatigue more
often (52.3% vs. 34.0%; RR 1.3 [CI 1.0–1.5]; p= 0.025), and had a
lower RAND-36 vitality score (61.4 vs. 66.3; mean difference
- 2.9 [CI - 5.3 to - 0.6]; p= 0.015) and a higher SFQ score (13.7
vs. 11.1; mean difference 1.4 [CI 0.5–2.3]; p= 0.002).The median
TSH of euthyroid subjects without previously known thyroid
disease was 1.4 mIU/L (interquartile range [IQR] 1.0–1.9). The
Table 2. Self-Reported Fatigue and Scores of the RAND-36 Vitality Subscale and SFQ
by Thyroid Function Class, in Subjects Free of Known Thyroid Disorder (N = 5897)
Self-reported fatigue RAND-36 vitality SFQ
Subjects n % RR [CI] Score RC [CI] Score RC [CI]
Euthyroidism 5439 34.0 Reference 66.3 Reference 11.1 Reference
Thyroid dysfunctiona 458 39.6 1.1 [0.9–1.3] 65.4 - 0.3 [ - 1.9–1.4] 11.6 0.1 [- 0.5–0.7]
Overt thyrotoxicosis 9 55.6 1.6 [0.7–3.9] 63.9 - 1.9 [ - 12.8–9.0] 13.8 2.4 [- 1.5–6.3]
Subclinical thyrotoxicosis 196 37.0 1.0 [0.8–1.3] 65.0 - 0.8 [ - 3.3–1.7] 11.9 0.4 [- 0.5–1.3]
Subclinical hypothyroidism 216 42.8 1.1 [0.9–1.4] 66.0 0.3 [ - 2.1–2.7] 11.2 - 0.3 [- 1.2–0.6]
Overt hypothyroidism 22 28.6 0.8 [0.4–1.8} 67.6 1.7 [ - 5.5–8.8] 11.5 0.2 [- 2.5–2.9]
The relative risks (RRs) and regression coefficients (RCs) [with 95% confidence interval (CI)] were adjusted for gender, age, BMI, smoking
status, and comorbidity.
aOf the subjects with thyroid dysfunction, seven subjects had a serum TSH > 0.4 mIU/L and FT4 > 22 pmol/L, and eight subjects had a
serum TSH < 4.0 mIU/L and FT4 < 8 pmol/L.
Table 3. Self-Reported Fatigue and Scores of the RAND-36 Vitality Subscale and SFQ in Euthyroid Subjects,
Free of Known Thyroid Disorder, by TSH and FT4 Within the Normal Range (N = 5439)
Self-reported fatigue RAND-36 vitality SFQ
Subjects n % RR [CI] Score RC [CI] Score RC [CI]
TSH 0.4–1.0 mIU/L 1493 36.2 1.1 [0.97–1.2] 65.2 - 1.6 [- 2.6 to - 0.5]a 11.7 0.6 [0.2–1.0]a
TSH 1.0–2.0 mIU/L 2754 33.3 Reference 66.8 Reference 11.0 Reference
TSH 2.0–3.0 mIU/L 918 31.7 1.0 [0.8–1.1] 66.9 0.4 [- 0.9–1.7] 10.7 - 0.4 [- 0.9–0.1]
TSH 3.0–4.0 mIU/L 274 36.3 1.1 [0.9–1.4] 65.7 - 0.8 [- 2.9–1.3] 11.1 0.0 [- 0.8–0.8]
FT4 8.0–11.5 pmol/L 808 33.4 1.0 [0.9–1.2] 66.4 - 0.1 [- 1.5–1.2] 11.1 0.0 [- 0.5–0.5]
FT4 11.5–15 pmol/L 3517 33.3 Reference 66.6 Reference 11.0 Reference
FT4 15–18.5 pmol/L 1023 35.3 1.0 [0.9–1.1] 65.7 - 0.3 [- 1.5–0.9] 11.5 0.2 [- 0.3–0.6]
FT4 18.5–22 pmol/L 91 52.2 1.4 [1.0–1.9]
a 61.7 - 4.4 [- 8.1 to - 0.6]a 13.2 1.9 [0.4–3.3]a
The RRs and RCs [with CI] were adjusted for gender, age, BMI, smoking status, and comorbidity.
ap< 0.05.
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median TSH of subjects with known thyroid disease and TSH
levels within normal range did not differ: 1.4 mIU/L (IQR 0.9–
2.1).The median FT4 of euthyroid subjects without previously
known thyroid disease was 13.3 pmol/L (IQR 12.1–14.6). The
median FT4 of subjects with previously known thyroid disease
and serum TSH and FT4 within the normal range was
14.3 pmol/L (IQR 12.5–15.9). This differed significantly from
the FT4 levels of euthyroid subjects without previously known
thyroid disease (RC 0.80 [CI 0.5–1.1]; p< 0.05 after adjustment
for possible confounders).
Discussion
In this cross-sectional population study, we found an as-
sociation between the presence and severity of fatigue and
low-normal serum TSH levels and high-normal FT4 levels.
Although the magnitude of the differences was small and of
dubious clinical significance, these results raise the question
whether a serum TSH-value in the middle- or high-normal
range would represent an optimal thyroid function. Indeed,
the Rotterdam study has shown that a high-normal serum
TSH level is associated with a lower risk of atrial fibrillation
(16). However, other previous studies have shown a higher
risk of cardiovascular mortality, an association with a higher
blood pressure, a higher BMI, and a higher non–high-density
lipoprotein cholesterol in subjects with serum TSH-values
within the high-normal range (12–15,17). These findings
suggest that there may be different optimal serum TSH levels
for each medical condition and symptom.
Previous studies have reported conflicting results re-
garding the association of thyroid function and fatigue in the
general population. Canaris et al. reported more symptoms,
including an increase of tiredness in subclinically and
overtly hypothyroid subjects in comparison to euthyroid
subjects in the Colorado study (2). The Colorado thyroid
disease prevalence study was a large, cross-sectional popu-
lation study that examined the prevalence of abnormal
thyroid function by measuring the serum TSH and FT4 in
25,862 participants in a statewide health fair in Colorado in
1995. Besides the prevalence of thyroid dysfunction, the re-
lationship between abnormal thyroid function and symp-
toms was examined, among which, the symptom of feeling
more tired. Due to the larger study population, this study
comprised more subclinically and overtly hypothyroid
subjects in comparison to our study. Also, the symptom
feeling more tired was evaluated as an increase of tiredness
over time instead of tiredness as a current symptom. This
may explain the discrepancy with our results with respect to
Table 4. Self-Reported Fatigue and Scores of the RAND-36 Vitality Subscale and SFQ
by TPOAb Subclasses in Subjects Free of Known Thyroid Disorder (N = 5897)
Self-reported fatigue RAND-36 vitality SFQ
Subjects n % RR [CI] Score RC [CI] Score RC [CI]
Total population
TPOAbs - 5150 34.3 Reference 66.3 Reference 11.2 Reference
TPOAbs + 747 35.3 1.0 [0.8–1.1] 66.0 0.5 [ - 0.9–1.8] 11.3 - 0.1 [ - 0.6–0.4]
Euthyroid subjects
TPOAbs - 4870 33.9 Reference 66.3 Reference 11.1 Reference
TPOAbs + 569 34.6 1.0 [0.8–1.1] 66.3 0.7 [ - 0.9–2.2] 11.4 0.1 [ - 0.5–0.7]
Subjects with thyroid dysfunction
TPOAbs - 280 48.9 Reference 65.6 Reference 12.0 Reference
TPOAbs + 178 42.1 0.8 [0.6–1.2] 65.2 0.5 [ - 3.0–4.0] 11.1 - 1.2 [ - 2.5–0.1]
The RRs and RCs [with CI] were adjusted for gender, age, BMI, smoking status, and comorbidity.
Table 5. Prevalence of Fatigue and Scores of the RAND-36 Vitality Subscale and SFQ
by Medical History of Thyroid Disease
Self-reported fatigue RAND-36 vitality subscale SFQ
Subjects n % RR [CI] Score RC [CI] Score RC [CI]
Total population
Without previously known thyroid disorder 5897 34.4 Reference 66.2 Reference 11.2 Reference
With previously known thyroid disorder 328 50.0 1.2 [1.0–1.4]a 61.8 - 2.6 [ - 4.5 to - 0.6]a 13.5 1.3 [0.6–2.1]a
Euthyroid subjects
Without previously known thyroid disorder 5439 34.0 Reference 66.3 Reference 11.1 Reference
With previously known thyroid disorder 221 52.3 1.3 [1.0–1.5]a 61.4 - 2.9 [ - 5.3 to - 0.6]a 13.7 1.4 [0.5–2.3]a
Subjects with thyroid dysfunction
Without previously known thyroid disorder 458 39.6 reference 66.4 Reference 11.6 Reference
With previously known thyroid disorder 107 45.1 1.1 [0.8–1.5] 62.6 - 1.9 [ - 5.8–1.9] 13.2 1.4 [ - 0.1–2.8]
The RRs and RCs [with CI] were adjusted for gender, age, BMI, smoking status, and comorbidity.
ap < 0.05.
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the prevalence of fatigue in patients with overt or subclinical
hypothyroidism. Another explanation is that the partici-
pants of our study were not aware of the fact that thyroid
function was tested, and therefore this could not have af-
fected their response to the questionnaire. Grabe et al. (11)
found no increase in mental or physical complaints, includ-
ing fatigue, in subjects with subclinical or overt hypo- or
hyperthyroidism in a population study with 3790 partici-
pants of the Study of Health in Pomerania. Interestingly,
subjects with overt or subclinical hyperthyroidism seemed to
have less complaints in comparison to euthyroid subjects,
but the prevalence of the symptom fatigue did not differ
significantly (11). These results are in accordance with the
results in our study. Neither of the previous studies exam-
ined the association between TSH and FT4 within the normal
range and fatigue or used a validated test to establish the
severity of fatigue.
In contrast with the association we found between the
presence and severity of fatigue and low-normal TSH and
high-normal FT4 levels, we could not detect an obvious as-
sociation between overt or subclinical hypo- or hyperthy-
roidism and fatigue. This is also in contrast with the high
prevalence of fatigue in patients with known thyroid dys-
function (5–7). One explanation may be that if thyroid dys-
function has led to complaints like tiredness, it is likely that
these subjects have sought medical care and received therapy.
These subjects were excluded from our analyses. This may
have led to an underestimation of the association between
thyroid dysfunction and fatigue in our study. Another ex-
planation may be that thyroid dysfunction of the subjects in
this study is less severe compared with the population con-
sisting of referred patients. A third explanation might be that
in our study, only a single blood sample was obtained for
determining the thyroid hormone levels. Thyroid dysfunction
can be transient and normalize spontaneously. These subjects
might be less likely to complain of fatigue.
However, based on our data, we believe that this is not the
only explanation for this discrepancy. The prevalence of fa-
tigue in subjects with thyroid dysfunction in our study was
39.6%, only slightly higher than the prevalence of fatigue in
euthyroid patients, which was 34.0%. Because of the high
prevalence of both fatigue and thyroid (subclinical) dys-
function in the general population, it is likely that many
patients who seek medical care because of fatigue, happen to
be tired and by coincidence also have thyroid dysfunction,
without any causal relationship. Patients with fatigue are
more likely to have their thyroid status tested by the general
practitioner and thyroid dysfunction will be found more
often, despite the absence of a causal relationship. This kind
of selection bias is called confounding by indication (28).
Theoretically, treatment of thyroid dysfunction in these
cases would not resolve the symptom fatigue. Although it is
difficult to extend these findings of an epidemiological study
to individual patients, we hypothesize that this might be the
reason why in clinical practice, a subset of patients with
thyroid dysfunction still complain of fatigue, despite optimal
treatment and despite achieving euthyroidism. Our finding
that subjects with known thyroid disease reported fatigue
more often, had a lower RAND-36 vitality score and had a
higher SFQ score, despite normal serum TSH and FT4 levels,
supports this hypothesis. This hypothesis is also compatible
with previous randomized controlled studies in which
treatment of subclinical hypothyroidism and subclinical
thyrotoxicosis had no effect on health-related quality of life
and symptoms (29,30).
Confounding by indication is one explanation for the
finding that subjects with known thyroid disease reported
fatigue more often, regardless of normal serum TSH and FT4
levels. Another explanation might be that the underlying
disease, like chronic autoimmune thyroiditis, Graves’ dis-
ease, or goiter, may cause fatigue regardless of the presence
of thyroid dysfunction or is associated with other diseases,
which may cause fatigue as well. Also, the fact that subjects
are aware of having thyroid disease may influence their
feeling of well-being and have an impact on their quality of
life, which may result in a higher fatigue score. In addition,
subtle abnormalities in the dynamics of thyroid hormone
secretion, even within the normal range, should be consid-
ered; the FT4 levels of subjects with known thyroid disease
and with thyroid hormone levels within the normal range
were slightly higher in comparison to euthyroid subjects
without known thyroid disease. Similar to our results,
Engum et al. have reported an association between previ-
ously known thyroid disease and depression and anxiety,
independent of thyroid function, in a large population-based
survey (31).
We found no association between the level of TPOAbs and
fatigue. This is in contrast with the recently described asso-
ciation between TPOAbs and both the presence of fatigue and
the vitality subscale score of the SF-36 questionnaire (18).
Perhaps, the difference in study population is the cause of this
discrepancy. The study of Ott et al. (18) comprised euthyroid
women with a benign goiter. Our study was population
based, comprising both men and women, without known
thyroid disease.
Our study has some limitations. Because of the cross-
sectional observational nature of our study, no causal rela-
tionship or lack of causal relationship can be determined.
Second, the results in the group of patients with overt hypo-
thyroidism or thyrotoxicosis should be interpreted cautiously,
as only a small number of participants were found to have an
overt thyroid dysfunction. We did not measure triiodothy-
ronine (T3), so we might have missed some cases of overt
thyrotoxicosis in subjects with normal FT4 and elevated T3
and misclassified those subjects as having a subclinical thy-
rotoxicosis. Third, antibodies against thyroglobulin were not
measured in this epidemiological survey, so we might have
missed some cases of autoimmune thyroiditis (32). Fourth,
despite the fact that the subscale vitality of the RAND-36 and
the SFQ we used have been validated as excellent tools to
screen for the presence and severity of fatigue, these instru-
ments have only a limited value with respect to their ability to
differentiate and quantify all the dimensions of fatigue. It is
difficult to establish the clinical meaningfulness of a 1-point
higher score on a fatigue scale. Finally, we cannot rule out a
selection bias due to a difference in fatigue or thyroid function
in the responders group versus the nonresponders group and
we cannot rule out the presence of other, unmeasured possi-
ble confounders.
In conclusion, within the normal range of TSH and FT4,
fatigue seemed more severe in subjects with low-normal TSH
levels and high-normal FT4 levels than middle-normal TSH
and FT4 levels, although the effect was small. Subjects with a
history of thyroid disease, but with normal TSH and FT4
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concentrations, experience more fatigue than the general
population. The reasons for this are unclear, but subtle ab-
normalities in the dynamics of thyroid hormone secretion
should be considered.
Disclosure Statement
The authors declare that no competing financial interests
exist.
References
1. Bjøro T, Holmen J, Kru¨ger Ø, Midthjell K, Hunstad K,
Schreiner T, Sandnes L, Brochmann H 2000 Prevalence of
thyroid disease, thyroid dysfunction and thyroid peroxidase
antibodies in a large, unselected population. The Health
Study of Nord-Trøndelag (HUNT). Eur J Endocrinol
143:639–647.
2. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC 2000 The
Colorado thyroid disease prevalence study. Arch Intern Med
160:526–534.
3. Hollowell JG, Staehling NW, Flanders WD, Hannon WH,
Gunter EW, Spencer CA, Braverman LE 2002 Serum TSH,
T4, and thyroid antibodies in the United States population
(1988 to 1994): National Health and Nutrition Examina-
tion Survey (NHANES III). J Clin Endocrinol Metab 87:
489–499.
4. Hoogendoorn EH, Hermus AR, de Vegt F, Ross HA, Verbeek
AL, Kiemeney LA, Swinkels DW, Sweep FC, den Heijer M
2006 Thyroid function and prevalence of anti-thyroperoxidase
antibodies in a population with borderline sufficient iodine
intake: influences of age and sex. Clin Chem 52:104–111.
5. Canaris GJ, Steiner JF, Ridgway EC 1997 Do traditional
symptoms of hypothyroidism correlate with biochemical
disease? J Gen Intern Med 12:544–550.
6. Lazarus JH 1997 Hyperthyroidism. Lancet 349:339–343.
7. Lindsay RS, Toft AD 1997 Hypothyroidism. Lancet 349:413–
417.
8. Jameson JL, Weetman AP 2010 Disorders of the thyroid
gland. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL,
Longo DL, Jameson JL, Loscalzo J (eds) Harrison’s Principles
of Internal Medicine, 17th edition. Available online at
www.accessmedicine.com/content.aspx?aID = 2877285
9. Jaeschke R, Guyatt G, Cook D, Harper S, Gerstein HC 1994
Spectrum of quality of life impairment in hypothyroidism.
Qual Life Res 3:323–327.
10. Watt T, Hegedu¨s L, Rasmussen AK, Groenvold M, Bonnema
SJ, Bjorner JB, Feldt-Rasmussen U 2007 Which domains of
thyroid-related quality of life are most relevant? Patients and
clinicians provide complementary perspectives. Thyroid
17:647–654.
11. Grabe HJ, Vo¨lzke H, Lu¨demann J, Wolff B, Schwahn C, John
U, Meng W, Freyberger HJ 2005 Mental and physical com-
plaints in thyroid disorders in the general population. Acta
Psychiatr Scand 112:286–293.
12. Asvold BO, Vatten LJ, Nilsen TI, Bjøro T 2007 The associa-
tion between TSH within the reference range and serum
lipid concentrations in a population-based study. The
HUNT Study. Eur J Endocrinol 156:181–186.
13. Asvold BO, Bjøro T, Nilsen TI, Vatten LJ 2007 Association
between blood pressure and serum thyroid-stimulating
hormone concentration within the reference range: a
population-based study. J Clin Endocrinol Metab 92:841–
845.
14. Asvold BO, Bjøro T, Nilsen TI, Gunnel D, Vatten LJ 2008
Thyrotropin levels and risk of fatal coronary heart disease.
The HUNT study. Arch Intern Med 168:855–860.
15. Fox CS, Pencina MJ, D’Agostino RB, Murabito JM, Seely EW,
Pearce EN, Vasan RS 2008 Relations of thyroid function to
body weight: cross-sectional and longitudinal observations
in a community-based sample. Arch Intern Med 168:587–
592.
16. Heeringa J, Hoogendoorn EH, van der Deure WM, Hofman
A, Peeters RP, Hop WC, den Heijer M, Visser TJ, Witteman
JC 2008 High-normal thyroid function and risk of atrial fi-
brillation: the Rotterdam study. Arch Intern Med 168:2219–
2224.
17. Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BH
2007 Thyroid function is associated with components of the
metabolic syndrome in euthyroid subjects. J Clin Endocrinol
Metab 92:491–496.
18. Ott J, Promberger R, Kober F, Neuhold N, Tea M, Huber JC,
Hermann M 2011 Hashimoto’s thyroiditis affects symptom
load and quality of life unrelated to hypothyroidism: a
prospective case-control study in women undergoing thy-
roidectomy for benign goiter. Thyroid 21:161–167.
19. Hays RD, Sherbourne CD, Mazel RM 1993 The RAND 36-
Item Health Survey 1.0. Health Econ 2:217–227.
20. Ware JE Jr, Sherbourne CD 1992 The MOS 36-item short-
form health survey (SF-36). I. Conceptual framework and
item selection. Med Care 30:473–483.
21. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes
M, Sanderman R, Sprangers MA, te Velde A, Verrips E 1998
Translation, validation, and norming of the Dutch language
version of the SF-36 Health Survey in community and
chronic disease populations. J Clin Epidemiol 51:1055–1068.
22. VanderZee KI, Sanderman R, Heyink J 1996 A comparison
of two multidimensional measures of health status: the
Nottingham Health Profile and the RAND 36-Item Health
Survey 1.0. Qual Life Res 5:165–174.
23. Alberts M, Smets EM, Vercoulen JH, Garssen B, Bleijenberg
G 1997 ‘Abbreviated fatigue questionnaire’: a practical tool
in the classification of fatigue. Ned Tijdschr Geneeskd
141:1526–1530.
24. Alberts M, Vercoulen JHMM, Bleijenberg G 2001 Assess-
ment of fatigue–the practical utility of the subjective feeling
of fatigue in research and clinical practice. In: Vingerhoets
(ed) A Assessment in Behavioral Medicine, first edition,
Brunner-Routledge, London, pp 301–327.
25. Callas PW, Pastides H, Hosmer DW 1998 Empirical com-
parisons of proportional hazards, poisson, and logistic re-
gression modeling of occupational cohort data. Am J Ind
Med 33:33–47.
26. Mittlbock M, Heinzl H 2001 A note on R2 measures for
poisson and logistic regression models when both models
are applicable. J Clin Epidemiol 54:99–103.
27. Zou G 2004 A modified poisson regression approach to
prospective studies with binary data. Am J Epidemiol
159:702–706.
28. Knottnerus JA, Knipschild PG, Sturmans F 1989 Symptoms
and selection bias: the influence of selection towards spe-
cialist care on the relationship between symptoms and di-
agnosis. Theor Med 10:67–81.
29. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin
RH, Franklyn JA, Hershman JM, Burman KD, Denke MA,
Gorman C, Cooper RS, Weissman NJ 2004 Subclinical thy-
roid disease: scientific review and guidelines for diagnosis
and management. JAMA 291:228–238.
1242 VAN DE VEN ET AL.
30. Villar HC, Saconato H, Valente O, Atallah AN 2007 Thyroid
hormone replacement for subclinical hypothyroidism. Co-
chrane Database Syst Rev 18:CD003419.
31. Engum A, Bjoro T, Mykletun A, Dahl AA 2002 An
association between depression, anxiety and thyroid
function—a clinical fact or an artefact? Acta Psychiatr
Scand 106:27–34.
32. McLachlan SM, Rapoport B 2004 Why measure thyroglob-
ulin autoantibodies rather than thyroid peroxidase auto-
antibodies? Thyroid 14:510–520.
Address correspondence to:
Annenienke C. van de Ven, M.D.
Department of Endocrinology (471)
Radboud University Nijmegen Medical Centre
Geert Grooteplein 8
P.O. Box 9101
6500 HB Nijmegen
The Netherlands
E-mail: ac.ven@aig.umcn.nl
THYROID FUNCTION AND FATIGUE 1243
